Did you know that since the onset of COVID-19 at the end of March of this year the FDA has approved over 18 novel drugs, six of which were for biotech companies based in Massachusetts or with facilities in the Bay State? How are companies taking on the extraordinary challenges and obstacles of launching (or choosing not to launch) new drugs in the time of COVID-19? How are they educating and communicating with the audiences and stakeholders that are impacted?
Sponsored by the MassBio MarComm and Commercial forum working group.
MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.